Atlas Trials

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Clinical trial NCT07459634 · RECRUITING

Trial details

NCT number
NCT07459634
Sponsor
Jazz Pharmaceuticals
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive-stage Small-cell Lung Cancer
Start date
2026-08-30
Primary completion
2028-01-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.